Cargando…

A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane

PURPOSE: To compare the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide in pseudophakic patients with refractory diabetic macular edema (DME) due to epiretinal membrane (ERM). Study Design. This study is a randomized clinical trial (RCT). Participants. Twe...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelshafy Tabl, Ahmed, Tawfik Soliman, Tarek, Anany Elsayed, Mohamed, Abdelshafy Tabl, Marwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799353/
https://www.ncbi.nlm.nih.gov/pubmed/35096422
http://dx.doi.org/10.1155/2022/7947710
_version_ 1784642051989569536
author Abdelshafy Tabl, Ahmed
Tawfik Soliman, Tarek
Anany Elsayed, Mohamed
Abdelshafy Tabl, Marwa
author_facet Abdelshafy Tabl, Ahmed
Tawfik Soliman, Tarek
Anany Elsayed, Mohamed
Abdelshafy Tabl, Marwa
author_sort Abdelshafy Tabl, Ahmed
collection PubMed
description PURPOSE: To compare the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide in pseudophakic patients with refractory diabetic macular edema (DME) due to epiretinal membrane (ERM). Study Design. This study is a randomized clinical trial (RCT). Participants. Twenty-three nonvitrectomized pseudophakic eyes of 23 subjects (9 M and 14 F with mean age: 54.8 years) with refractory DME due to ERM. METHODS: The eyes were randomized to suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA) (n = 13 eyes) or intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA) (n = 10 eyes) and were evaluated at baseline and 1 and 3 months after injection to assess outcome measures. Main Outcome Measures. Changes in best-corrected visual acuity (BCVA) (primary outcome), central foveal thickness (CFT) by optical coherence tomography (OCT), and intraocular pressure (IOP) measurement (secondary). RESULTS: Baseline median BCVA (logMAR) was 1.0 (range 0.8–1.0) in both groups, improved within the SCTA group to 0.8 on the 1(st) and 3(rd) months, while in the IVTA group, median BCVA changed to 0.8 and 0.9 on the 1(st) and 3(rd) months, respectively. No significant differences were noted between groups regarding BCVA at baseline (P=0.927), and 1(st) (P=0.605) and 3(rd) months (P=0.313). Regarding mean CFT, no significant differences were observed at baseline (P=0.353) and at the first month (P=0.214) between both groups, while at the third month, CFT was significantly higher in the IVTA group (385 um) than in the SCTA group (323 um) (P=0.028). Mean IOP was significantly higher in the IVTA group (15 mmHg) on 1(st) month than in the SCTA group (12 mmHg) (P=0.011); after 3(rd) month, IOP was significantly higher within the IVTA group (18 mmHg) than SCTA (14 mmHg) (P=0.028). No significant difference was noted between both groups at baseline IOP (P=0.435). CONCLUSIONS: Both SCTA and IVTA are effective in reduction of CFT and improvement of patients' visual acuity, but with a higher recurrence rate and rise in IOP after IVTA when compared to SCTA. Both treatments have temporary effects with the possibility of recurrence of DME and the need for retreatment.
format Online
Article
Text
id pubmed-8799353
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87993532022-01-29 A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane Abdelshafy Tabl, Ahmed Tawfik Soliman, Tarek Anany Elsayed, Mohamed Abdelshafy Tabl, Marwa J Ophthalmol Research Article PURPOSE: To compare the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide in pseudophakic patients with refractory diabetic macular edema (DME) due to epiretinal membrane (ERM). Study Design. This study is a randomized clinical trial (RCT). Participants. Twenty-three nonvitrectomized pseudophakic eyes of 23 subjects (9 M and 14 F with mean age: 54.8 years) with refractory DME due to ERM. METHODS: The eyes were randomized to suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA) (n = 13 eyes) or intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA) (n = 10 eyes) and were evaluated at baseline and 1 and 3 months after injection to assess outcome measures. Main Outcome Measures. Changes in best-corrected visual acuity (BCVA) (primary outcome), central foveal thickness (CFT) by optical coherence tomography (OCT), and intraocular pressure (IOP) measurement (secondary). RESULTS: Baseline median BCVA (logMAR) was 1.0 (range 0.8–1.0) in both groups, improved within the SCTA group to 0.8 on the 1(st) and 3(rd) months, while in the IVTA group, median BCVA changed to 0.8 and 0.9 on the 1(st) and 3(rd) months, respectively. No significant differences were noted between groups regarding BCVA at baseline (P=0.927), and 1(st) (P=0.605) and 3(rd) months (P=0.313). Regarding mean CFT, no significant differences were observed at baseline (P=0.353) and at the first month (P=0.214) between both groups, while at the third month, CFT was significantly higher in the IVTA group (385 um) than in the SCTA group (323 um) (P=0.028). Mean IOP was significantly higher in the IVTA group (15 mmHg) on 1(st) month than in the SCTA group (12 mmHg) (P=0.011); after 3(rd) month, IOP was significantly higher within the IVTA group (18 mmHg) than SCTA (14 mmHg) (P=0.028). No significant difference was noted between both groups at baseline IOP (P=0.435). CONCLUSIONS: Both SCTA and IVTA are effective in reduction of CFT and improvement of patients' visual acuity, but with a higher recurrence rate and rise in IOP after IVTA when compared to SCTA. Both treatments have temporary effects with the possibility of recurrence of DME and the need for retreatment. Hindawi 2022-01-21 /pmc/articles/PMC8799353/ /pubmed/35096422 http://dx.doi.org/10.1155/2022/7947710 Text en Copyright © 2022 Ahmed Abdelshafy Tabl et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Abdelshafy Tabl, Ahmed
Tawfik Soliman, Tarek
Anany Elsayed, Mohamed
Abdelshafy Tabl, Marwa
A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title_full A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title_fullStr A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title_full_unstemmed A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title_short A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane
title_sort randomized trial comparing suprachoroidal and intravitreal injection of triamcinolone acetonide in refractory diabetic macular edema due to epiretinal membrane
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799353/
https://www.ncbi.nlm.nih.gov/pubmed/35096422
http://dx.doi.org/10.1155/2022/7947710
work_keys_str_mv AT abdelshafytablahmed arandomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT tawfiksolimantarek arandomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT ananyelsayedmohamed arandomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT abdelshafytablmarwa arandomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT abdelshafytablahmed randomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT tawfiksolimantarek randomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT ananyelsayedmohamed randomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane
AT abdelshafytablmarwa randomizedtrialcomparingsuprachoroidalandintravitrealinjectionoftriamcinoloneacetonideinrefractorydiabeticmacularedemaduetoepiretinalmembrane